Nav: Home

Disparities in outcomes for rare pediatric cancer suggest unequal access to primary care

October 05, 2015

BOSTON (October 5, 2015) - Disparities in outcomes for children with retinoblastoma -- a rare eye tumor usually discovered in routine pediatric check-ups -- suggest unequal access to primary care, researchers from Dana-Farber/Boston Children's Cancer and Blood Disorders Center report in a study published in the journal JAMA Pediatrics. Although virtually all the children in the study survived, Hispanic children and children who lived in disadvantaged areas were more likely to lose an eye due to late diagnosis.

White children and children who live in areas with a higher socio-economic status were more likely to have been diagnosed early enough that physicians could preserve their eye and vision. In a review of 830 cases recorded in the National Cancer Institute's Surveillance, Epidemiology and End Results (SEER) registries, researchers examined results for children under age 10 whose cases of retinoblastoma were recorded between January 1, 2000, and December 31, 2010. They looked at race and ethnicity and analyzed county-based data on poverty, educational attainment, language isolation, crowding, unemployment and proportion of immigrants.

The study found:

  • At the time of diagnosis, the disease had spread beyond the eye in 33 percent of Hispanic children, compared with 20 percent of non-Hispanic children.

  • At diagnosis, disease had spread beyond the eye in 28 percent of children from high-poverty areas, compared with 20 percent of other children. Similar disparities were found in other measures of socio-economic status.

  • Three-quarters (74.5 percent) of Hispanic children had the diseased eye surgically removed, compared with two-thirds (67.5 percent) of non-Hispanic children and less than two thirds (63 percent) of non-Hispanic white children. Among non-Hispanic black and Asian children, 74 percent had their eye removed.

  • Three-quarters (76 percent) of children living in disadvantaged counties had their eye removed, compared to less than two-thirds (64 percent) who lived in advantaged counties.

Retinoblastoma is usually detected during a routine pediatrician visit with a so-called "red reflex" test: When the clinician flashes a light in the child's eye, a white reflection from the retina - rather than a healthy red reflection -- indicates the possible presence of a tumor. The disease typically affects children under age 5, and most cases are diagnosed before age 2. Early diagnosis makes it easier for clinicians to salvage the eye, either through laser therapy or cryo- (cold) or thermo- (heat) therapy delivered by an ophthalmologist, or through chemotherapy delivered to the eye. If the tumor has spread deep into the eye socket or beyond, a surgeon must remove the affected eye.

"Because retinoblastoma is most often diagnosed during well-child visits, the disparities uncovered in this study raise questions about inequities in primary care that go beyond the few children who develop this rare cancer," said senior author Carlos Rodriguez-Galindo, MD, clinical director of the Solid Tumor Center at Dana-Farber/Boston Children's. "The findings also tell us that, despite the advances of recent decades in the care of children with cancer, disparities still exist. These disparities may impact children in different ways, depending on the type of cancer and treatment received. It is very important to perform disease-specific studies of disparities to better assess the impact of this problem."

Many children with retinoblastoma lose an eye, regardless of race, ethnicity or socio-economic status, because most children present with advanced intraocular disease, notes co-author Paola Medina Friedrich, MD, a pediatric oncologist at Dana-Farber/Boston Children's. This, she says, suggests that there is room for improved awareness among pediatricians about screening children during routine visits or room for improvement in skills and conditions during clinic visits that would help pediatricians detect the tumor's characteristic white reflection at earlier stages of the disease.

"Even without considering disparities, most children present with large intraocular tumors. Ideally we should detect these tumors when they are small and have not compromised vision," Friedrich said. "The guidelines recommend routine vision checks, including the red reflex check on every well child visit. This is particularly important during the first two years."

Disparities in access to treatment may also contribute to outcomes that differ by race, ethnicity and socioeconomic status, the researchers note. Salvaging a patient's eye requires access to sophisticated, multi-disciplinary care, as well as multiple clinic visits and treatment administration, all which may be more difficult for families facing economic, cultural or language barriers. "As treatments for retinoblastoma become increasingly complex," the study warns, "disparities may worsen."
Dana-Farber/Boston Children's Cancer and Blood Disorders Center -- the nation's top pediatric cancer center, according to U.S. News & World Report's 2015-16 listing. - brings together two internationally known research and teaching institutions to provide comprehensive care for pediatric oncology and hematology patients since 1947. The Harvard Medical School affiliates share a clinical staff that delivers inpatient care and surgery at Boston Children's Hospital and most outpatient care atDana-Farber Cancer Institute.

Dana-Farber Cancer Institute

Related Cancer Articles:

Radiotherapy for invasive breast cancer increases the risk of second primary lung cancer
East Asian female breast cancer patients receiving radiotherapy have a higher risk of developing second primary lung cancer.
Cancer genomics continued: Triple negative breast cancer and cancer immunotherapy
Continuing PLOS Medicine's special issue on cancer genomics, Christos Hatzis of Yale University, New Haven, Conn., USA and colleagues describe a new subtype of triple negative breast cancer that may be more amenable to treatment than other cases of this difficult-to-treat disease.
Metabolite that promotes cancer cell transformation and colorectal cancer spread identified
Osaka University researchers revealed that the metabolite D-2-hydroxyglurate (D-2HG) promotes epithelial-mesenchymal transition of colorectal cancer cells, leading them to develop features of lower adherence to neighboring cells, increased invasiveness, and greater likelihood of metastatic spread.
UH Cancer Center researcher finds new driver of an aggressive form of brain cancer
University of Hawai'i Cancer Center researchers have identified an essential driver of tumor cell invasion in glioblastoma, the most aggressive form of brain cancer that can occur at any age.
UH Cancer Center researchers develop algorithm to find precise cancer treatments
University of Hawai'i Cancer Center researchers developed a computational algorithm to analyze 'Big Data' obtained from tumor samples to better understand and treat cancer.
New analytical technology to quantify anti-cancer drugs inside cancer cells
University of Oklahoma researchers will apply a new analytical technology that could ultimately provide a powerful tool for improved treatment of cancer patients in Oklahoma and beyond.
Radiotherapy for lung cancer patients is linked to increased risk of non-cancer deaths
Researchers have found that treating patients who have early stage non-small cell lung cancer with a type of radiotherapy called stereotactic body radiation therapy is associated with a small but increased risk of death from causes other than cancer.
Cancer expert says public health and prevention measures are key to defeating cancer
Is investment in research to develop new treatments the best approach to controlling cancer?
UI Cancer Center, Governors State to address cancer disparities in south suburbs
The University of Illinois Cancer Center and Governors State University have received a joint four-year, $1.5 million grant from the National Cancer Institute to help both institutions conduct community-based research to reduce cancer-related health disparities in Chicago's south suburbs.
Leading cancer research organizations to host international cancer immunotherapy conference
The Cancer Research Institute, the Association for Cancer Immunotherapy, the European Academy of Tumor Immunology, and the American Association for Cancer Research will join forces to sponsor the first International Cancer Immunotherapy Conference at the Sheraton New York Times Square Hotel in New York, Sept.

Related Cancer Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Digital Manipulation
Technology has reshaped our lives in amazing ways. But at what cost? This hour, TED speakers reveal how what we see, read, believe — even how we vote — can be manipulated by the technology we use. Guests include journalist Carole Cadwalladr, consumer advocate Finn Myrstad, writer and marketing professor Scott Galloway, behavioral designer Nir Eyal, and computer graphics researcher Doug Roble.
Now Playing: Science for the People

#530 Why Aren't We Dead Yet?
We only notice our immune systems when they aren't working properly, or when they're under attack. How does our immune system understand what bits of us are us, and what bits are invading germs and viruses? How different are human immune systems from the immune systems of other creatures? And is the immune system so often the target of sketchy medical advice? Those questions and more, this week in our conversation with author Idan Ben-Barak about his book "Why Aren't We Dead Yet?: The Survivor’s Guide to the Immune System".